23andMe Upgrades to Higher-Density Array, Offers Detailed Analysis of Rx Response, Disease Risk
November 25, 2010
23andMe Upgrades to Higher-Density Array, Offers Detailed Analysis of Rx Response, Disease Risk
With the new platform, the company is hoping to provide greater coverage of drug-metabolizing enzymes and transporters, and analyze additional genes associated with drug response.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- 2010 in Review: Genomic Medicine Experiences Growing Pains of Regulation, Economics, and Litigation
January 12, 2011 / Pharmacogenomics Reporter - 23andMe to 'Experiment' with Different Price Models in 2011
January 5, 2011 / Pharmacogenomics Reporter - DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter - What's In a Name? Experts Question Bill Calling DTC Genomics 'Post-CLIA Bioinformatics Services'
September 30, 2009 / Pharmacogenomics Reporter - At Investor Confab, Illumina Details 'Enormous' DTC Demand as Market Shifts to Less Complex Chips
May 21, 2013 / BioArray News